Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.48 |
| ▸ | ACHE | P22303 | 4/20 | 0.45 |
| ▸ | CNR1 | P21554 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5438052 | 0.95 | CNR2 (0.52) | CNR2ACHECNR1L3MBTL1MAPT | |
| SCHEMBL22151026 | 0.81 | MAPT (0.52) | CNR2ACHECNR1L3MBTL1MAPT | |
| SCHEMBL22151047 | 0.78 | CNR2 (0.58) | CNR2ACHECNR1L3MBTL1MAPT | |
| SCHEMBL5443607 | 0.78 | KDM4C (0.39) | CNR2ACHECNR1KMT2AKDM4C | |
| SCHEMBL5464933 | 0.77 | CNR2 (0.46) | CNR2ACHECNR1L3MBTL1MAPT | |
| SCHEMBL6069615 | 0.77 | CNR2 (0.58) | CNR2ACHECNR1L3MBTL1LMNA | |
| SCHEMBL23467039 | 0.76 | KDM4C (0.40) | CNR2ACHECNR1KMT2AKDM4C | |
| SCHEMBL29770896 | 0.76 | KDM4C (0.40) | CNR2ACHECNR1KMT2AKDM4C | |
| SCHEMBL22151034 | 0.75 | CNR2 (0.44) | CNR2ACHECNR1L3MBTL1MAPT | |
| SCHEMBL5443540 | 0.75 | CNR2 (0.55) | CNR2ACHECNR1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101098857-A | Nitro indazole derivatives | ASTRAZENECA AB (SE) | 2008-01-02 | — | — | CN | disclosed |
| US-20070265325-A1 | Nitro Indazole Derivatives | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265325-A1 | Nitro Indazole Derivatives | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265325-A1 | Nitro Indazole Derivatives | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | US | disclosed |
| EP-1814864-A1 | NITRO INDAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006052189-A1 | NITRO INDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265325-A1 | Nitro Indazole Derivatives | NOS3, CYP3A43, NOS2 | CNR2 210/4885ACHE 58/4885CNR1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.